VERBATIM: A randomised controlled trial of aripiprazole for the treatment of auditory verbal hallucinations in borderline personality disorder

This dataset originates from a 12-week, single-centre, randomized controlled trial (RCT) that examines the efficacy of aripiprazole versus placebo in treating auditory verbal hallucinations (AVHs) in 15-25 year-olds diagnosed with Borderline Personality Disorder (BPD). The study addresses a critical gap in clinical practice by testing conventional pharmacotherapy used for AVHs in schizophrenia, applied to similar symptoms in BPD, a practice not currently supported by NHMRC guidelines for BPD treatment. Participants were followed for a total of 27 weeks, with assessments on AVH severity, BPD symptoms, general psychopathology, functioning, and the experience of psychotic symptoms. The study also explored changes in the neurobiological mechanisms underlying AVHs as influenced by treatment.